During follow-up only four cardiovascular adverse events were regarded by the investigator to be drug-related ( grade @ lymphostasis and grade @ lymphoedema , each in one patient in the trastuzumab group , and grade @ thrombosis and grade @ deep vein thrombosis , each in one patient in the chemotherapy-alone group ) .